Klaus Rudolf

This inventor holds 87 USPTO granted patents and 11 published patent applications, plus 5 CIPO patents and 29 EPO patents, primarily in CGRP Antagonists (CPC class C07D403-12). Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co Kg, Dr. Karl Thomae Gmbh. Active years: 1990-2024.

USPTO Granted Patents = 87 (Patent Applications = 11)

% Patents Active = 95.4

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 29 (Patent Applications = 26)

Average Co-Inventor Count = 7.4

ph-index = 12

Forward Citations = 640(Granted Patents)

Forward Citations (Not Self Cited) = 538(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Biberach DE (1993)
Biberach, DE (1990 - 2009)
Warthausen, DE (2001 - 2024)

Company Filing History:

51 out of 1,560

Boehringer Ingelheim International Gmbh

patents

13 out of 194

Boehringer Ingelheim Pharma Gmbh & Co Kg

Centrexion Therapeutics Corporation

patents

5. 3 out of 149

Boehringer Ingelheim Pharma Kg

9. 3 out of 834,350

Other

patents

Years Active: 1990-2024

Loading Chart...

Areas of Expertise:

CGRP Antagonists

Somatostatin Receptor Agonists

Neutrophil Elastase Inhibitors

Pyrimidine Derivatives

Bicyclic Dihydropyrimidinones

Positive Allosteric Modulators

Morpholine Compounds

Tetrahydro Derivatives

Piperazine Derivatives

Imidazole Compounds

Bronchodilators

Pharmaceutical Compositions

87 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071403 - Modulators of complex I (2024-08-27),

2. 11795147 - Modulators of complex I (2023-10-24),

3. 10675268 - Somatostatin receptor subtype 4 (SSTR4) agonists (2020-06-09),

4. 10577336 - Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists (2020-03-03),

5. RE47493 - Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity (2019-07-08),

6. 10166214 - Somatostatin receptor subtype 4 (SSTR4) agonists (2019-01-01),

7. 10071974 - Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists (2018-09-11),

8. 9789082 - Somatostatin receptor subtype 4 (SSTR4) agonists (2017-10-17),

9. 9371282 - Somatostatin receptor subtype 4 (SSTR4) agonists (2016-06-21),

10. 9346816 - 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them (2016-05-24),

11. 9115093 - Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity (2015-08-25),

12. 8952014 - Pyrimidine derivatives which are CGRP—antagonists (2015-02-10),

13. 8937176 - Compounds (2015-01-20),

14. 8889677 - Substituted triazoles useful as mGlu5 receptor modulators (2014-11-18),

15. 8846948 - Compounds (2014-09-30),

Title: Klaus Rudolf: A Visionary Inventor Shaping Tomorrow's Technology Landscape

Introduction:

Klaus Rudolf, a brilliant inventor hailing from Warthausen, DE, is a true pioneer in the realm of technology. With a staggering 86 patents to his name, Rudolf's innovative spirit and unwavering dedication to finding solutions for the challenges of the future make him a standout figure in the world of innovation.

Latest Patents:

Among Klaus Rudolf's latest patents are groundbreaking inventions that push the boundaries of scientific discovery. His work on "Modulators of complex I" revolutionizes the function of mitochondrial complex I, while his development of "Somatostatin receptor subtype 4 (SSTR4) agonists" offers new possibilities in treating medical disorders related to SSTR4.

Career Highlights:

Rudolf's illustrious career has seen him contribute significantly to renowned companies such as Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharma GmbH & Co. KG. His innovative work within these organizations has not only garnered acclaim but has also paved the way for cutting-edge advancements in the field of technology.

Collaborations:

Collaborating with esteemed colleagues such as Henri Doods and Dirk Stenkamp, Klaus Rudolf has fostered a collaborative environment that thrives on innovation and excellence. Together, they have pushed the boundaries of what is possible and inspired the next generation of inventors and innovators.

Conclusion:

In conclusion, Klaus Rudolf's passion for innovation and his relentless pursuit of excellence have solidified his position as a visionary inventor. His impact on technology is profound, and his legacy continues to inspire countless individuals worldwide. Klaus Rudolf stands as a beacon of creativity, guiding us towards a brighter and more innovative future.